REGENXBIO to Host Investor Event on Wet AMD Treatment
REGENXBIO will host an investor event on October 20, 2026, to review the clinical program for surabgene lomparvovec (sura-vec) in wet age-related macular degeneration (wet AMD).
Biotechnology company REGENXBIO will host an investor event on October 20, 2026, in New York to review the clinical program for surabgene lomparvovec (sura-vec) in wet age-related macular degeneration (wet AMD). The event precedes the anticipated topline pivotal trial data readout expected in the fourth quarter of 2026.
The event will feature an overview of the clinical program by REGENXBIO management and leading retina specialists. Discussions will cover the treatment landscape, unmet need, the ATMOSPHERE® and ASCENT® pivotal trials, and commercial readiness for sura-vec in wet AMD.
Key opinion leaders participating include Dr. Gaurav Shah of California Pacific Medical Center, Dr. Arshad Khanani of Sierra Eye Associates, Dr. Lejla Vajzovic of Duke University School of Medicine, Dr. Rahul Khurana of Northern California Retina Vitreous Associates, and Dr. Ramanath Bhandari of Springfield Clinic Eye Institute.
REGENXBIO focuses on developing AAV gene therapies for rare and retinal diseases. Its pipeline includes RGX-202 for Duchenne muscular dystrophy, clemidsogene lanparvovec (RGX-121) for MPS II, and RGX-111 for MPS I, in partnership with Nippon Shinyaku. Sura-vec for wet AMD and diabetic retinopathy is being developed in collaboration with AbbVie.